Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib for symptomatic NF1-related plexiform neurofibroma in adults
NL-OMON28237Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Erasmus MC. Primary endpoint: Objective response rate. Started Jul 2020; status: recruiting.
02
Drugs
trametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NL-OMON28237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28237.